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1. Introduction 
Earlier investigations have shown corticotropin 
(ACTH) to produce pharmacological effects previously 
thought o be specific for opioid peptides and alka- 
loids. Corticotropm peptides and opioid peptides 
both produce characteristic grooming behaviour in 
rats on intraventricular injection [ 11, and have also 
been shown to inhibit the electrically evoked contrac- 
tion of the mouse vas deferens in vitro [2] in a 
naloxone reversible manner. More recently, cortico- 
tropin related peptides were found to produce similar 
analgesic effects to /I-endorphin on injection directly 
into the periaqueductal gray of the rat [3]. These 
observations along with the report [4] that cortico- 
tropin l-24 can displace [3H]naloxone from opiate 
receptors in rat brain membranes strongly suggests 
that corticotropin peptides can interact with the 
opiate receptor. This paper describes astructure activ- 
ity study of the opiate receptor interaction of corti- 
cotropin and related peptides using [3H]dihydromor- 
phine and [ ‘Hlnaloxone as labelled ligands. The data 
is correlated with the predicted receptor conformation 
of the enkephalins and corticotropin and explains the 
molecular basis for the interaction of corticotropin 
with the opiate receptor, suggesting that the receptor 
environment induces the N-terminal region of cortico- 
tropin into an o-helical conformation. 
ology [6]. The peptide resins, BOC.Ser(Bzl).Tyr(Bzl). 
Ser(Bzl).Met.Glu(Bzl).His.Phe.Arg(Tos).Trp.Gly-resin 
and the corresponding peptidoresins for the 2-10 
and 3-l 0 analogs, were treated with anhydrous 
methanol saturated with ammonia to remove the pep- 
tide from the resin as the protected Gin’ amides. The 
protected peptides were purified by gel filtration 
through Sephadex LH-20 eluted with dimethylform- 
amide. The purified peptides were deprotected by 
treatment with trifluoroacetic acid followed by 
sodium in liquid ammonia reduction in the presence 
of excess free tryptophan. The peptides were finally 
purified by gel filtration through Sephadex G-25 
eluted with 50% acetic acid. The resulting peptides 
had the required ammo acid compositions after 
hydrolysis in 6 M HCl containing 1% phenol. 
2.2. Tissue preparation 
Sprague-Dawley rats (250 g) were decapitated and 
the brains without cerebellum were rapidly removed. 
Tissue was homogenised in 20 vol. ice cold 0.32 M 
sucrose in a Potter glass homogeniser fitted with a 
Teflon pestle. The whole homogenate was centrifuged 
at 1000 X g for 15 min at 4°C; the pellet was discarded 
and the supematant was centrifuged at 50 000 X g 
for 30 min at 4°C. The resultant pellet was hypo- 
tonically lysed and washed 3 times in 0.01 M 
Tris-HCl (pH 7.4). The final pellet was suspended in
this buffer, divided into small aliquots and stored at 
-20°C. 
2. Materials and methods 
2.3. Receptor binding assay 
2.1. Pep tides 
Corticotropin was isolated from porcine pituitary 
glands as in [5]. The peptides Gln’ACTH (l-l 0) 
amide, Gln’ACTH (2-l 0) amide and Gln’ACTH 
(3-10) amide was synthesised by solid-phase method- 
To aliquots of membrane suspension (1mg protein), 
in 0.05 M Tris-HCl, 0.1 M NaCl, 0.1% BSA and 
0.01% bacitracin (pH 7.4) buffer, was added [3H]- 
naloxone (50 Ci mmol-‘, final cont./tube 1 nM) or 
[3H]dihydromorphine (73 Ci mmol-‘, final cont./ 
hblished by Elsevier Biomedical Press 
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tube 0.5 nM)in the presence of known concentrations 
of test peptide; the final volume of the incubation 
mixture was 1 ml. After incubation at 30°C for 
15 min the suspension was centrifuged (16 000 X g; 
3 min), the supernatant removed by aspiration and 
the pellet superficially washed with ice cold 0.05 M 
Tris-HCl, 0.1 M NaCl (pH 7.4) buffer. The tips of 
the tubes containing the pellet were removed and the 
pellet resuspended in 0.5 ml water. After addition of 
6 ml Packard 299 Scintillation fluid the radioactivity 
was assayed by liquid scintillation counting at 30% 
efficiency. 
2.4. Conformational predictions 
The methods used were essentially those in [7,8] 
for the prediction of secondary structure in proteins. 
3. Results and discussion 
The structural requirements for the stimulation of 
the opiate receptor by opioid peptides has been exten- 
sively studied using synthetic analogs [9] but these 
studies alone have given little insight into fie receptor 
conformation of the enkephalins. Theoretical 
approaches [lO,ll], however, have proved a useful 
starting point for evaluating structure activity data in 
terms of receptor conformation. The empirical meth- 
ods of Chou and Fasman [7,8] for predicting protein 
conformation have been used to predict the confor- 
mation of small peptides in the proteinaceous envi- 
ronment of their receptors [121, and for enkephalin, 
a P-bend at the l-4 position has been proposed 
[ 11 ,121. Support for this hypothesis has come from 
the X-ray crystallography of leucine-enkephalin 
showing the presence of such a P-bend [ 131. In this 
conformation it is possible to explain the ability of 
the opioid peptides and alkaloids to interact with the 
same receptor. There is a remarkable similarity in the 
orientation of functional groups in the peptides and 
morphine alkaloids, particularly the very potent 
oripavines [ 111. The similarities in methionine- 
enkephalin reside with the tyrosine sidechain and 
a-amino group in position 1, the phenylalanine side- 
chain in position 4 and the methionine sidechain in 
position 5. 
The ability of corticotropin to bind to the ‘opiate’ 
receptor should involve some or all of these deter- 
minants. The possibility that the tyrosine sidechain at 
position 2 in corticotropin could correspond to the 
210 
tyrosine in enkephalin at position 1 which is essential 
for opiate receptor interaction is examined using syn- 
thetic peptides corresponding to Gln’ACTH(1 -1 O)- 
NH2, Gln’ACTH(2-1 O)NH2 and Glr?ACTH(3-1 O)- 
NH2. The GlnS substitution in corticotropin has little 
effect on biological activity [ 141 and was used in this 
work to facilitate the solid phase synthesis: 
H.S;r.Tyr.Ser .Met.Gln.His.Phe.Arg.Trp.Gly.NH, GlnsACTH(l-lO)NH, 
2 3 4 5 6 7 8 910 
H.Tyr.GlyGly.Phe.Met.OH 
1234 5 
Methionine-enkephalin 
GlnSACTH(2-10) has Ser’ missing and consequently 
the a-amino group of the Tyr’ exposed, and 
Gh?ACTH(3-10)NH2 has the Tyr’ residue under 
investigation removed. Table 1 shows the ability of 
these peptides, as well as corticotropin (l-39) and 
the opiate alkaloids and peptides, to displace [3H]- 
naloxone and [3H]dihydromorphine from rat brain 
synaptosomal membranes. Corticotropin (l-39) 
shows a significant preference for the dihydromor- 
phine-labelled receptor with an affinity as high as 
those reported for some of the less active enkephalin 
analogs 191. Removal of residues 1l-39 as in 
GlnSACTH(l -10)NH2 leads to a reduction of affinity 
but clearly shows the 1 l-39 residues of corticotropin 
not to be essential for interaction with the opiate 
receptor; these residues do however appear to be 
responsible for the discrimination of corticotropin 
between the dihydromorphine and naloxone labelled 
receptors. The receptor affinity of GlnSACTH(2-lO)- 
NH2 is 3-4-fold higher than GlnSACTH( l-1 0)NH2 
for both ligands. This would be expected if Tyr* in 
corticotropin were equivalent to Tyr’ in enkephalin, 
Table 1 
Concentrations for 50% inhibition of [ “Hldihydromorphine 
and [ 3H]naloxone binding to brain membranes by cortico- 
tropin, corticotropin related peptides, opioid peptides 
and alkaloids 
[ ‘H] Dihydro- [‘HI Naloxone 
morphine (nM) (nM) 
ACTH 0.1 0.75 
GWACTH(1 -lO)NH, 11 16 
GhPACTH(2-lO)NH, 3 7 
GhPACTH(3-lO)NH, 20 35 
Met-Enkephalin 0.008 0.009 
p-Endorphin 0.0022 0.0026 
Dihydromorphine 0.0036 0.002 
Naloxone 0.0024 0.0018 
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since removal of Ser’ from corticotropin exposes the 
o-amino group of Tyr* found in enkephalin and known 
to be important for opiate receptor binding [9]. The 
equivalence of the 2 tyrosines is also demonstrated by 
the dramatic drop in receptor affinity when Tyr* is 
subsequently removed, as in Gln5(3-lO)NH,. The 
changes in opiate receptor affinity of Gh?ACTH- 
(1 -10)NH2 when Ser’ and Tyr’ are removed parallel 
those observed when, for instance, the Glycyl and 
Tyr’ residues are removed fromN-glycyl-methionine- 
enkephalin [15]. Therefore, it would appear that 
Tyr* in corticotropin serves the same function as 
Tyr’ in enkephalin at the opiate receptor. 
Extensive structure activity work on the hormonal 
activity of corticotropin [161 has .shown that the core 
sequence which is vital for corticotropin receptor 
stimulation is contained in the N-terminal 10 residues; 
consequently, these residues hould be those princi- 
pally involved in receptor interaction. This area of 
corticotropin is predicted to be helical in the protein- 
aceous environment of the receptor [121 using the 
conformation prediction methods in [ 7,8]. 
If Tyr* in corticotropin in an a-helical conforma- 
tion is aligned with Tyr’ in a P-bend conformation 
there is a remarkable similarity in orientation of iden- 
tical sidechains in the 2 molecules; these conforma- 
tions are shown diagramatically in fig.1. Tyr’, Met4 
and Phe’ sidechains incorticotropin fall in exactly the 
same spatial orientation as Tyr’, Phe4 and Met’ in 
enkephalin, these being the residues essential for the 
biological activity of enkephalin at the opiate receptor. 
We conclude from these results that it is the N-ter- 
minal region of corticotropin that interacts with the 
opiate receptor and it is the structural similarity of 
this region of corticotropin in an o-helical conforma- 
tion with the receptor conformation of enkephalin 
that accounts for this overlap in activity. The physio- 
logical receptor for corticotropin in the central 
nervous ystem has yet to be demonstrated, however, 
it is probably closely involved with the opiate recep- 
tor in view of the common biosynthetic origin of the 
endorphins and corticotropin [17-201 and the similar 
distribution of these peptides in the central nervous 
system [21], probably within the same neuron. 
Fig.]. Comparison of the predicted a-helical conformation of the N-terminal region of corticotropin (left) and the predicted 
P-bend conformation of methionine enkephalin (right). The numbers refer to the residue numbers of the 2 molecules, only the 
relevant sidechains are shown for clarity. 
211 
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